NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in BioMedWire editorial coverage highlighting FDA clearance of the company Investigational New Drug (“IND”) application to begin a randomized, double-blind, placebo-controlled phase 2 trial of Lucid-MS in people with multiple sclerosis (“MS”). Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (“PAD2”) and target demyelination rather than broadly suppressing the immune system. The editorial notes that Lucid-MS previously completed phase 1 testing in healthy volunteers, with the company reporting favorable safety and tolerability, and discusses Quantum BioPharma parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School involving a PET imaging tracer designed to quantify demyelination.
The coverage also highlights recent analyst attention, including Rodman & Renshaw initiation of coverage with a Buy rating and $8 price target, as Quantum BioPharma prepares Lucid-MS for its first clinical testing in people with MS. The editorial places the company alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology and neurological diseases.
To view the full press release, visit https://nnw.fm/cwPHa
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in BioMedWire editorial coverage highlighting FDA clearance of the company Investigational New Drug (“IND”) application to begin a randomized, double-blind, placebo-controlled phase 2 trial of Lucid-MS in people with multiple sclerosis (“MS”). Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate designed to inhibit peptidyl arginine deiminase 2 (“PAD2”) and target demyelination rather than broadly suppressing the immune system. The editorial notes that Lucid-MS previously completed phase 1 testing in healthy volunteers, with the company reporting favorable safety and tolerability, and discusses Quantum BioPharma parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School involving a PET imaging tracer designed to quantify demyelination.
The coverage also highlights recent analyst attention, including Rodman & Renshaw initiation of coverage with a Buy rating and $8 price target, as Quantum BioPharma prepares Lucid-MS for its first clinical testing in people with MS. The editorial places the company alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology and neurological diseases.
To view the full press release, visit https://nnw.fm/cwPHa
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
